Henlius Aims to Launch More Biosimilars in US, EU
PositiveFinancial Markets

Shanghai Henlius Biotech is making strides in the biosimilars market, with CEO Jason Zhu Jun expressing growing confidence in their international partnerships. As the company aims to expand its offerings in the US and EU, this move could significantly enhance access to affordable medications, benefiting patients and healthcare systems alike. Henlius's focus on biosimilars reflects a broader trend in the pharmaceutical industry towards more cost-effective treatment options.
— Curated by the World Pulse Now AI Editorial System